SSA
TVRD

Schonfeld Strategic Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Schonfeld Strategic Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,132
Closed -$746K – 2737
2025
Q3 		$746K Buy
+19,132
New +$545K ﹤0.01% 1518
2020
Q3 		– Sell
-527
Closed -$324K – 1725
2020
Q2 		$324K Buy
+527
New +$291K 0.01% 965
2016
Q2 		– Sell
-278
Closed -$62K – 546
2016
Q1 		$62K Buy
+278
New +$83K 0.03% 294

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Schonfeld Strategic Advisors's TVRD Position: Q4 2025 in Review

Schonfeld Strategic Advisors sold out of Tvardi Therapeutics (TVRD) in Q4 2025, closing a stake of 19,132 shares — an estimated $746K sold.

Schonfeld Strategic Advisors first reported a position in TVRD in Q1 2016 and held it in 3 quarters. The position peaked at $746K in Q3 2025. 67 funds tracked by Wall St. Rank hold TVRD as of Q4 2025.

  • Schonfeld Strategic Advisors reported no remaining Tvardi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 19,132 Tvardi Therapeutics shares in Q4 2025, an estimated $746K.
  • Schonfeld Strategic Advisors first reported a position in Tvardi Therapeutics in Q1 2016 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's Tvardi Therapeutics position peaked at $746K in Q3 2025.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.